# JBI-802

Source: https://onco.cc/drugs/jbi-802/  
OnCo record `jbi-802` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JBI-802 is a small-molecule inhibitor from Jubilant Therapeutics Inc., in registered phase 2 trials for myeloproliferative neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms.

## Summary

JBI-802 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Jubilant Therapeutics Inc., in myeloproliferative neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms. Described in the registry record as a corest inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: JBI-802
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a corest inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of JBI-802: https://clinicaltrials.gov/search?intr=JBI-802

## Connected records

- cancers: [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- trials: [Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis](https://onco.cc/trials/nct07612280/)

---
JSON: https://onco.cc/api/v1/entities/jbi-802.json